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endotlwlti and vprrular smooth muscle cells have t&n dw.lopd 
recently. Th include the genetic mcditkatiw ofe&th&m in 
vttm and implantation i viva on arterial segments, direct intec- 
Major advances in recombinant deoxyribonucleic acid 
(DNA) technology and in our understanding of eukaryotiL 
gene regulation have resulted in the emergence of gene 
therapy as a potential treatment for inherited and acquired 
diseases. Gene therapy is the introduction of normal genes 
into the somatic cells of patients to correct an inherited or 
acquired disorder through the synthesis of missing or defer- 
tive gene products in viva (I). Although no diseases have yet 
been treated by gene therapy, several gene transfer protc- 
cals. which introduce recombinant genes as markers to 
study disease. have recently been undertaken (2). 
The expression of recombinant genes in viva at specific 
arterial sites represents a novel approach to !he study of 
vascularbiolagy and eventually the therapeutic management 
of human vascular disease. Genes expressed in endothelial 
and vasadar smooth muscle cells can produce local &ecls 
by their ability to influence the function and integrity of the 
arterial wall. In addition. because of their proximity to the 
bloodstream. they can also be used to deliver therapeutic 
factors into local circulations tu all&t sysiemic diseases. 
Therefore. vascular cell gene transfer technology is poten- 
tially applicable to a variety of diseases. both inherited and 
acquired, and in particular to restenosis after angioplasty. 
This review focuses on attempt, to target genes to cells and 
tissues relevant to cardiovascular disorders. 
Strategies for Gene Therapy 
Merhods of Gene Modification 
A variety ofapproaches to human gene transfer are under 
current investigation (3). In general, three methods of gene 
modification can be *rfwmed: gene replacement. gene 
correction and gene augmentation. 
II Gew replacemrnr entails the removal of a mutant 
gene sequence from the host genome and its replacement 
with a normal functional gene. Although partial gene re- 
placement hrough targeting has been accomplished swcess- 
fully in the laboratory. it is still impractical fat gene therapy 
because OF technical difficulties. 
?I Analogous to gene replacement. gene mrrecrion at- 
tempts to alter Ihe defective poriiiln of a mutant gene and 
renders the gene functional withoiit precisely changing the 
gene back to its natural foorm. Although gene correction is 
technically feasible. it is beywtd the bounds of current 
technology in viva Recently, genetic targeting of foreign 
sequences leading to r&is gene sequence modification 
has been accomplished in several mammalian systems 
(4.5). 
3) Gene orrgmenration is a more established technique 
far modifying the expression of mutant genes in defective 
cells by inrroducing foreign narmal genetic sequences into 
the host genome. leaving defective host genes unaltered. 
With these techniques. it is possible to restore genetic 
function by the introduction of functional genes into nonspe- 
citic sites in the host genome without removal of the non- 
functional mutant gene. Although mutational events could 
arise from the integration of foreign sequences at ectopic 
sires in the genome. this complication has not yet arisen in 
practice. For this reason. this appmach to gene augmenta- 
tion has received considerable attention. 
Table 1. Experimental Methadr of Gene Transfer 
Methods of Gene Transfer 
There are a variety of physical, chemical and viral meth- 
ods for introducing genes into cells (Table I). Viral vectors 
have been successfully used to infect cells and transfer genes
that are incorporated stably into the host eenome (6). How- 
ever, there are important &fety issues that roust be exam- 
ined before these methods can be widely used in humans. 
Most important is the need to demonstrate that these vectors 
do not give rise to infectious agents that have the potential to 
caw disease. lo the case of retroviral vectors, a variety of 
precautions have been taken to reduce this likelihood, 
including altering the viral genotne to be replication defec- 
tive. 
An adequate delivery system for introducing genes into 
cells is an essential component of successful gene transfer. 
Several requirements must be met: I) high efficiency of 
transmission; 21 stable replication ofthe foreign DNA, either 
as an inlegrated tmnsgene or as an extrachromosomal ek- 
meat; 3) appropriate and regulated expression in the target 
tissue; and 4) adequate safety over the time of transfer and 
the life of the host. 
Physical and Chemical Techniques 
A variety of techniques have been used in the laboratory 
to introduce genes into cells in tissue culture. Physical 
methods for the introduction of DNA into cells include 
microinjection and electropotation. Microinjection of plas- 
mid DNA into a host cell can be achieved by using a special 
apparatus under microscopic control (7). Although this 
method is reasonably efficient, only one cell can he injected 
at a time and transfection of a large number of cells is not 
feasible. An alternative physical approach, electroporation. 
is the transport of DNA into the cell by disrupting the 
surface membrane with a rapid pulse of high voltage current 
(8). This method has been used to transfer a variety of genes 
into diiTerent cells, but the studies have been experimental 
and the technique has not been applied to human tissue. 
Recently, it was shown (9) that plasmid DNA injected 
directly into skeletal muscle is stably expressed in viva 
Exogenous DNA can also be introduced into cells by 
chemical method;, mcludiag coprecipitation with calcium 
phosphate and mcotporation of DNA into liposomes (IO). 
The longevity and stability of recombinant gene expression 
after these techniques are under investigation. 
Virus Vectors 
To improve the efficiency of delivery into mammalian 
cells, viral vectors have been used as an alternative to the 
physical or chemical methods just described. A variety of 
viruses have now been adapted as vectors, includiy aden- 
oviruses (I ). retroviruscs (6) and DNA viruses (12). Retro- 
viruses offer a number of advantages as a gene delivery 
s~stetn. Their aenetic structure is well characterized and 
they efficiently&fect a variety of cell types. These vectors 
oroduce efficient infection followed hv intenration. kadinn to 
itable gene expression. Although ret~oviraivectors haveihe 
potenlial to fomt wild-type rewmbinants leading to unregu- 
lated replication in the host, this complication can be mini- 
mized by altering the viral genome to render the viros 
unlikely to replicate. 
Retmvintses. The most useful vectors for the efficient 
introduction of oreign genes have been derived from marine 
and avian retroviruses, in particular, the Maloney murine 
leukemia virus. These viruses are amphotmpic; that is, they 
will infect multiple host species. A vector is constructed by 
initially deleting three structural genes required for viral 
replication (gag, pnl and env genes) fmm the viral geooroe 
(13). These include the gag gene. which encodes for group- 
specific antigens, the poi gene, which encodes reverse 
traoscriptase and an integrase, and the env gene, which 
encodes the envelope protein. For&a DNA for the gene of 
interest is ligated into the deleted genome of the virus, which 
retains a sequence required for viral Packaging. The retro- 
virus now lacks the structural gews required for replication 
and contains the foreign gene. The replicationdefective 
retroviral vector is introduced into a packaging cell line into 
which the gag, pal and em genes, devoid of packaging 
signals, have been previously transfected (Fig. I) (14). These 
structural geoes, provided in tmns in the packaging cell, 
allow production of a virus particle containing the defective 
RNA of the foreign gene. and it is capable of infecting a cell 
once. The infectious retroviral vector infects the host cell. 
the foreigo DNA is inserted into a random site in the host 
genome and the host cell may express the foreign gene. 
Single vatsus molliple gene veetws. The simplest vectors 
contain a single gene. In this form, a single gene is ligated 
into the defective retroviral genome, and this gene is regu- 
lated by the long terminal repeat sequences of the native 
virus. Mulfiple gene vectors incorporate more than one 
(generally two) genes into the viral backbone, often under 
r&tlatio~ of s&rate promoters. The second gene is coot- 
manly a selectable marker (that is. drug resistance gene) 
introduced along with the foreign gene so that relatively pure 
populations of cells expressing the foreign gene can be 
selected in tissue culture. 
Complications. In theory, complications of these vectors 
could arise in several ways. Retroviruses and their vectors 
carriers to convey therapeutic agents that might include 
anticoagulant. vasodilator. angiogeoic or growth factors. 
Genetic modification of endothelial cells then could be a 
therapeutic approach to the treatment of many acquired 
vascular disorders. including hypertension. atherosclerosis 
and rcstenosis. Alternatively, the myocardiil cell is also a 
potential target for gene transfer to promote angiogeoesis in 
regions of injured myocardium or correct inheiited aboor- 
malitics of royocytes. Finally. the treatment of familial 
hyperchoiesterolemia. which results from the genetic deli- 
ciency of low density lipoprotein (LDL) receptors. may be 
amenable to gene therapy by targeting the LDL receptor 
gene into heoatocytes of hvwrcholesterolemic oatierds (21). 
Figure 1. Construction of a retroviral vector. Foreign genes are 
lieated into a defective retmviral eenome lackine the ~tnclural 
g&s required forvinlmpliiation, bit retaining a s&ewe for viral 
packaging. A packaging cell tine is tmnrfected with a plarmid 
containing the structural genes for replication (gag [Gl. pal (PI and 
em [El), but devoid of packaging signals. The r.. ptkation-&feClive 
retmviralvectorisintroducedintothepac~agingcellline andavims 
particle is produced. BAG = beta-galactosidase: LTR = long 
temdnal repeat. Reprinted from N&xl (IS) with permission. 
are thought to integrate into random sites in the cell geooroe. 
although some inlegration at preferred sites has bee.1 ob- 
served. Random integration c&d potentially lead to inser- 
tional mutagenesis through t e interruption of cellular genes 
or through the insertion of retmviral regulatory sequences 
that modulate the expressioo of cellular genes. In practice. 
this complication has oat been observed. 
Anorher porenriol problem with the use of defectivr 
retroviral wcmrs is the appearance of wild-type virus in 
producer cells through the recombination between the traos- 
fated vector alasmid and eodo~enous retmvitwlike se- 
quences. To reduce the possibii&s for productive recom- 
biition, helper cell lines that express the gag, pal and env 
genes have been produced from separate plasmids with 
independent selectable markers (14). More than one recom- 
bination event is required to generate a wild-type virus and 
the likelihood of producing a wild-type virus is greatly 
reduced. 
Vascular Biology and Cardiovascular Disease 
Genetic Modification of Endothelial Cells 
Because of the considerable morbidity and mortality 
associated with cardiovascular diseases, they are likely 
candidates for gene transfer and therapy. Various cell types 
may be potential targets. including endothelial and vascular 
smooth muscle cells. Endothelial cells contribute to the 
patboRettesis of a!herosclerosis because they regulate hemo- 
stasis (l&17) and modulate smooth muscle cell growth and 
tone ULI-20). One approach to the treatment of vascular 
disease is to express genes at specific sites in the circulation 
that might ameliorate the process in situ. Because endothe- 
lial cells are found at diseand sites, they represent logical 
Eoddh&l .xfi p i&&r io vitro. Gene traosfer to 
the endothdium has been accomplished in vitro. Early 
studies by Feller et al. (22) demonstrated that endothelii 
cQs could be infected with murioe sarcoma viruses. Am- 
phorropic murine leukemia viruses cootaioing the ras oocw 
gene have been constructed and introduced into human 
umbilical vein ettdothelii cells. The genetically modified cell 
lines retained prowties characteristic of ditlerentiated en- 
dothelial cells. For example. van Willebmod factor was 
synthesized and secreted normally. These studies demort- 
strated that eodotkbal cells could be modified in vitro with 
preservation of endotbelial phenotype, owrphdogy and 
function. 
More recently. Zwiebel et al. (23) transduced recombi- 
nant genes into eodothelial cells with use of retroviral 
vectors. Rabbit aortic endothetial cells were infected with 
three retroviral vectors. Two of the vectors carried genes for 
nonsecreted proteinsaodthe thirdvectorcontaioedagrowth 
hormone gene, ail of which were successfully expressed in 
these cells. 
Implantation and Expression of Gene~rcally 
ModiJied Endorhelium In Viva 
In vivodelivery dgnr pmdwlsto tk vawdahue. In our 
initial experiments (24) we asked whether eodothelial cells 
could be genetically modified in vitro sod then implanted 
onto a local arterial segment in viva. Such a model system 
would provide an approach for the in viva delivery of gene 
products to the vasculature. To test these hypotheses, we 
first established a primary line of endotbelial cells in tissue 
culture, which were derived from the Yucatan minipig, a 
naturally occurring atherosclerotic model. The eodothelial 
cell identity of this line was confirmed by the presence of 
growth characteristics and morphology typical of porcine 
endothelium. Tote endothelial cells were infected in vitro 
with a retroviral vector expressing the enzyme beta- 
galactosidase. This enzyme. which is present in Escherichio 
co& was chosen as a marker because it stains blue with a 
chromagcnic substrate. The genetically modified endothe- 
lium, now expressing the foreign gene beta-galactosidase, 
was identified in tissue culture by blue staining. These 
modified endothelial cells also retained endothelial cell phe- 
Fire 2. Beta.galactosidase activity observed in endorhelialcells in 
viva Analysis of beta-gdactosidase expression in endothelial cells 
was performed by binlocbemical staining of a microscopic cross 
seclion of artery instilled with beta-galactoridareinfected endnhe- 
lial cells. Ammvs indicate the genetically mudificd endothelial cells. 
Magrift~.&m X250. reduced by 25%. Reprinted fram Nabel et al. 
124). with permission from the American Academy for the Advanee- 
ment of Science. 
notype demonstrated by analysis of acetylated LDL recep 
fur function. Both infected and uninfected endcnhelial cells 
expressed acetylated LDL receptors, whereas fibroblast 
cells did nut. 
The genetically altered endothelial cells were introduced 
into the iliofemaral anery of the Yucatan minipig by surgical 
exposure using a double balloon catheter (IJSCI. Bard Inc.). 
Infiation of the proximal and distal balloons creates a central 
space, which allows for the infusion of infected cells through 
an instillation part. A local region of the iliofemoral artery 
was mechanically denuded of endothelium tu allow adher- 
ence of genetically modified endothelial cells. The infected 
cells were instilled into the central space for 30 min. fullowed 
by removal of the catheter and restoration of anterogrude 
blood flow. 
Several weeks later, the arterial segments inoculated with 
the beta-galactosidase-expressing endothelium were re- 
moved and examined. Examination of the gross sections of 
artery segment after histochetnical staining revealed areas of 
blue coloration, indicating beta-galactosidase xpression. 
Under light microscopy, betn-galactosidase staining was 
observed in endothelial cells in the intima layer (Fig. 2). 
Examinatixt of control artery segments from sham-operated 
minipigs revealed no evidence cd beta-galactosidase expres- 
sion (24). 
Local bhbemkal and pharmacuhgic lreatment using en- 
dotbelisl cells. The introduction of genetically modified en- 
dothelial cells into the vascular wall by catheterization is an 
initial step in the develapment of localized biochemical and 
pharmacologic treatment for vascular disease using geneti- 
cally altered endathelium as u vector. Endotheliul cells may 
serve as a vehicle to intmduce therapeutic proteins into 
diseased arterial segments. This therapy has promise as a 
txtential treatment fur restenosis. After carunary angio- 
plasty. endotheliul cells expressing mwth inhibitor proteins 
could be introduced by catheter into the angioplasty site tu 
prevent local intimal hyperplasia and clinical restenosis. 
Because endothelial cells line all blood vessels, they are 
an ideal target to direct gene products into the bloodstream 
that can treat other systemic or inherited disorders. Fur 
example, the factor VIII gene could be intmduccd into a 
population ofendothelial cells (in a microcirculation) and the 
factor VIII pmtein, if synthesized in sutficient quantities by 
the modified endothelium. could in turn correct a hemuphilia 
disorder. 
The previous studies required that from the srune species 
(uia) endothelial cell lines he established in vitru before 
ieietic modification. This might pruve to be cumbersome in 
the eventual treatment of human disease because it might 
take several weeks to prepare genetically altered cells. It 
would be advantageous io directly modify vascular cells at 
the time of catheterization or angiuphtsty without much 
advanced preparation. 
iliuferiuxal artery ssgmmls (Fig. 3). To test the h&he& 
that vascular cells could be directly transduwd in viva. we 
perfurnxd experiments in which the retruviral vectur ex- 
pressing beta-galactosidase was directly instilled into the 
porcine iliofemoral artery using modilications of surgical and 
catheter techniques (25). Arterial segments were diictl~ 
infected by the retrovirus in viva and expressed bet& 
galactosidase activity for nt least 5 months. There was 
optimal expression of the recombinant gene at 2 tu 3 months. 
This time cuurse of gene expression would be adaptable to 
the treatment of restenosis, where averexpression of a 
growth inhibitor gene for several months might reduce 
intimal hyperplasia without longerterm effects. 
We found rhar a// three layers of the vessel were iufected 
by the refrovirus: intima, media and ndventitia. Further- 
more, using immunohistuchemical stains, we identified en- 
dothelird cells and vascular smooth muscle ce!!r as geneti- 
cally altered cells. Because them two cell types are primarily 
responsible for the synthesis and regulation of growth fat- 
tars that induce smooth muscle hyperplaia, they are ideal 
targets for genetic modification to inhibir their ubnomml 
growth. In addition, cells in the adventitia were also trans.- 
duced. 
TO ensure the safety of in viva retruviral infection, it is 
approach to improving the petfomtance of prosthetic vasat- 
lar grafts is to line the luminal sucfafe with ettdothelial cells 
that have been genetically modified with therapeutic proteins 
to prevent hrombosis or promote r population. Wilson et al. 
(26) implanted vascular grafts seeded with genetically mod- 
ified endothelial cells into the cairn carotid artery. In their 
studies. endothelii cells from canine jugular veins were 
infected with a beta-galactosidase-expressing retmviral vec- 
tor. Small diameter Dacrmt grafts were seeded at subcott- 
fluent densities with genetically altered endothelial cells and 
surgically implanted into the carotid artery of the dog from 
which the cells were harvested. Five weeks later, the grafts 
were harvested and analyzed. Scaoning electmo microscopy 
demonstrated a lining of cells with eodahelial morphology 
’ 
on the luminal swface in patent g&s. Each graft seeded 
1 
with infected endothelial cells expressed beta-gakxtoakiase 
activity on the lumen of the vessel. The conttalateral grafts 
’ 
/ 
seeded with mock-infected endolhclii cells did not demon- 
strate positive-staining cells. These studies demonstrate the 
feasibility of in viva impkmtation of vascular gifts seeded 
Figa 3. Cello in the intima and media directly transduced in viva 
by a beta.ga!xtosidas+exprersing retmvinl vector I otatths afta 
infection. Armws indicate betagalactolidaK_exprerring cells. *ub 
seqttcntly identified by immonobintoehen,dcal $udies as mdothelial 
$scular smooth muscle cells. Magttdicat~on x250. reduced by 
essential that replication-competent helper virus is not gett- 
erated. We examined pigs for the presence of helper virus. 
revene tmnscrip~ttse activity and beta-galactosidase activity 
in liver, lung, kidney and spleen and found no evidence of 
recombinant beta-gaiaclosidase activity outside of the focal 
arterial segment infected for up to 5 months. These resttlIs 
suggested that direct gene transfer can be achieved in viva 
by infection with a retroviral vector and that the genetic 
mwlilication is limited to the specific site of infection. 
Tnttsfedhm of ooreine iliofemoml arts with lioowme.3. 
Although the safeiy aspects of retroviru&w&ed gene 
transfer have been carefully examined. it would be desirable 
to petform human gene transfer without retroviruses. There- 
with &logous genetic&y modified endoth&l cells. This 
technology has obvious potential appliiations to the treat- 
stem of atherosclerotic disease and the design of new drug 
delivery systems. 
Vawttku sletds. One potential application of this technol- 
ogy is to populate vascular stettts with genetically modified 
endothelium, particularly to reduce the problem of local 
thrombosis. Dicheket al. (27) lined staiokss steel stems with 
sheep carotid ettdothelium geoetically altered to express 
tissue-type plasmiwgen activator @PA) and demonstrated 
high levels of secretion of human tPA in vitro li’om tram- 
duced sheep ertdothelium. These studies hold promise for 
the in viva placement of intravascular stents with genetically 
modified cells that could deliver a gene that mieht minimize 
local thrombosis. 
COnClOSiOUS 
Gene transfer can be utilized to introduce foreign DNA 
into somatic cells to study and treat many vascular diaor- 
ders. including abnormal &tl.w proliferation chatactcristic 
of restenosis. Despite their potetential biohazard risk, a vati- 
ety of precautions that have been taken appear to minimize 
the risks posed by these viruses. Retroviml vectors repre- 
sent attractive delivery vehicles for the introduction ofgenes 
into host cells. As an alternative approach, ttansfection of 
the an&d wall with liposome-DNA complexes holds ignif- 
icant potential. Gene transfer represents a novel and infor- 
fo&, to investigat~direct gene transfer into the arterial wall 
without rettoviral vectors, we directly transfected the par- 
tine iliofemoral artery with liposomes containing beta- 
gakwtosidase DNA, (25). The vascular ettdothelial and 
smooth muscle cells incorporate the liposomes and the 
beta-galactosidase gene is expressed in these cells for up to 
6 weeks. 
Endothelial Cell Seeding of Vmxlar 
marive method to study basic questions of vascttlar wall 
Prostheses and Stents 
biology, including the production and regulation of gmwth- 
promoting and growth-inhibiting factors. The techniques 
Pmsihelic vawtlsr grafts. Endothelial cell seeding of have obvious application to the treatment of many cardio- 
prosthetic vascular grafts with autologous endothelial cells vascular diseases, notably restenosis and athemsclemrir, 
promotes endothelialization of the lumittal surface. reduces and may eventually lead to the design of new drug delivery 
platelet accumulation and enhances patency rates. One systellls. 
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